Skip to main content

Table 1 Demographic and baseline characteristics

From: Inhaled β-agonist does not modify sympathetic activity in patients with COPD

Gender

Male, n (%)

21 (65.6)

Female, n (%)

11 (34.4)

Age [years]

 

61.2 ± 8.4

Body weight [kg]

 

81.5 ± 19.8

Height [cm]

 

174.6 ± 7.6

Body mass index [kg/m2]

 

26.5 ± 5.2

First diagnosis of COPD [months before screening)

 

59.0 ± 62.3

GOLD stage

II (moderate COPD), n (%)

14 (45.2)

III (severe COPD), n (%)

17 (54.8)

COPD symptoms

Breathlessness, n (%)

31 (96.9)

Cough, n (%)

24 (75.0)

Sputum production, n (%)

21 (65.6)

FEV 1 [L]

 

1.6 ± 0.4

FEV 1 [% predicted]

 

50.2 ± 9.9

FVC [L]

 

2.9 ± 0.8

FEV 1 /FVC [%]

 

54.5 ± 9.2

Smoking status

Previous smoker, n (%)

13 (40.6)

Smoker, n (%)

19 (59.4)

Cessation of smoking [months before screening]

 

54.0 ± 47.4

Pack years

 

43.1 ± 17.7

  1. COPD = Chronic obstructive pulmonary disease; FEV1 = forced expiratory volume in one second; FVC = forced vital capacity; GOLD = Global Initiative for Chronic Obstructive Lung Disease. Values are expressed as mean ± SD unless otherwise stated.